From Ospedale Generale Regionale Raffaello Silvestrini, Area Omogenea di
Cardiologia e Medicina, Perugia (P.V., C.B., A.C., R.G., I.Z., C.P.); Ospedale
Beato G. Villa, Città della Pieve (G.S.); and DIMISEM Università
di Perugia (G.R.), Italy. Presented in part at the Twelfth Scientific Meeting
of the American Society of Hypertension, San Francisco, Calif, May
27–31, 1996. Correspondence to Dr Paolo Verdecchia, Ospedale Generale
Regionale R. Silvestrini, Area Omogenea di Cardiologia e Medicina,
Località San Sisto, 06156 Perugia PG,
Italy.
Background—Increased left
ventricular (LV) mass predicts an adverse outcome in
patients with essential hypertension. The purpose of this study was to
determine the relation between changes in LV mass during
antihypertensive treatment and subsequent prognosis.
Methods and Results—Procedures including
echocardiography and 24-hour ambulatory blood
pressure (BP) monitoring were performed in 430 patients with essential
hypertension before therapy and after 1217 patient-years. Months or
years after the follow-up visit, 31 patients suffered a first
cardiovascular morbid event. The patients with a
decrease in LV mass from the baseline to follow-up visit were compared
with those with an increase in LV mass. There were 15 events (1.78 per
100 person-years) in the group with a decrease in LV mass and 16 events
(3.03 per 100 person-years) in the group with an increase in LV mass
(P=.029). In a Cox model, the lesser
cardiovascular risk in the group with a decrease in LV
mass (hazard ratio [HR], 0.46; 95% CI, 0.22 to 0.99) remained
significant (P=.04) after adjustment for age (HR, 1.06;
95% CI, 1.03 to 1.10; P=.0008) and baseline LVH at ECG
(HR, 3.85; 95% CI, 1.52 to 9.78; P=.012). In that
model, baseline LV mass bordered on statistical significance (HR, 1.01;
95% CI, 1.00 to 1.03; P=.06). In the subset with LV
mass >125 g/m2 at the baseline visit (26%
of subjects), the event rate was lower among the subjects who achieved
regression of LVH than in those who did not (1.58 versus 6.27 events
per 100 person-years; P=.002). This difference held in
the multivariate analysis (HR, 0.18; 95% CI,
0.05 to 0.68).
Conclusions—In essential hypertension, a reduction in LV mass
during treatment is a favorable prognostic marker that predicts a
lesser risk for subsequent cardiovascular morbid
events. Such an association is independent of baseline LV mass,
baseline clinic and ambulatory BP, and degree of BP reduction.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension
Key Words: hypertension • prognosis • hypertrophy • echocardiography • electrocardiography
This article has been cited by other articles:
 |
|
 |
|
  N. Reichek, R. B. Devereux, R. A. Rocha, R. Hilkert, D. Hall, D. Purkayastha, and B. Pitt Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension Hypertension, October 1, 2009; 54(4): 731 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-A Chang, Y.-J. Kim, H.-W. Lee, D.-H. Kim, H.-K. Kim, H.-J. Chang, D.-W. Sohn, B.-H. Oh, and Y.-B. Park Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart With Established Left Ventricular Hypertrophy Hypertension, September 1, 2009; 54(3): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Willis, M. Rojas, L. Li, C. H. Selzman, R.-H. Tang, W. E. Stansfield, J. E. Rodriguez, D. J. Glass, and C. Patterson Muscle ring finger 1 mediates cardiac atrophy in vivo Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H997 - H1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Raher, H. B. Thibault, E. S. Buys, D. Kuruppu, N. Shimizu, A.-L. Brownell, S. L. Blake, J. Rieusset, M. Kaneki, G. Derumeaux, et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2495 - H2502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Peterson, T. de Backer, A. Gabriel, V. Ilic, T. Vagaonescu, L. J. Appel, G. Contreras, C. Kendrick, S. Rostand, R. A. Phillips, et al. Prevalence and Correlates of Left Ventricular Hypertrophy in the African American Study of Kidney Disease Cohort Study Hypertension, December 1, 2007; 50(6): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Burnier, O. Phan, and Q. Wang High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2426 - 2429. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Struthers and C. Lang The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney Eur. Heart J., July 2, 2007; 28(14): 1678 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Buys, M. J. Raher, S. L. Blake, T. G. Neilan, A. R. Graveline, J. J. Passeri, M. Llano, T. M. Perez-Sanz, F. Ichinose, S. Janssens, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H620 - H627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Barrick, M. Rojas, R. Schoonhoven, S. S. Smyth, and D. W. Threadgill Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2119 - H2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Burns, M. U. Sivananthan, S. G. Ball, A. F. Mackintosh, D. A.S.G. Mary, and J. P. Greenwood Relationship Between Central Sympathetic Drive and Magnetic Resonance Imaging-Determined Left Ventricular Mass in Essential Hypertension Circulation, April 17, 2007; 115(15): 1999 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J. S Zaman, J. Sanders, A. M Crook, G. Feder, M. Shipley, A. Timmis, and H. Hemingway Cardiothoracic ratio within the "normal" range independently predicts mortality in patients undergoing coronary angiography Heart, April 1, 2007; 93(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Barrios, C. Escobar, A. Calderon, J. Pablo Tomas, S. Ruiz, J. L. Moya, A. Megias, O. Vegazo, and R. Fernandez Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 236 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 N. B. Mascarenhas, R. Muthupillai, B. Cheong, M. Pereyra, and S. D. Flamm Fast 3D cine steady-state free precession imaging with sensitivity encoding for assessment of left ventricular function in a single breath-hold. Am. J. Roentgenol., November 1, 2006; 187(5): 1235 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
|
|
Abstracts Heart, May 1, 2006; 92(suppl_2): A4 - A121. [Full Text] [PDF]
|
|
|
|
|
|
G. Schillaci, M. Pirro, G. Pucci, M. R. Mannarino, F. Gemelli, D. Siepi, G. Vaudo, and E. Mannarino Different Impact of the Metabolic Syndrome on Left Ventricular Structure and Function in Hypertensive Men and Women Hypertension, May 1, 2006; 47(5): 881 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Morganti Randomized Clinical Trials on Surrogate End Points: Are They Useful for Evaluating Cardiovascular and Renal Disease Protection in Hypertension? The Case for Yes J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S141 - S144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, S. Oikawa, S. Kawanishi, Y. Yamada, and M. Yokota Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res, February 15, 2006; 69(3): 726 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H T Smith, R U. Nair, D. Adamson, M. T Kearney, S. G Ball, and A. J Balmforth Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts J. Endocrinol., December 1, 2005; 187(3): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Y K Wong, S McSwiggan, N S J Kennedy, S Y S Wong, A Gavin, R S MacWalter, and A D Struthers Spectrum of cardiac abnormalities associated with long QT in stroke survivors Heart, October 1, 2005; 91(10): 1306 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sciacqua, A. Scozzafava, A. Pujia, R. Maio, F. Borrello, F. Andreozzi, M. Vatrano, S. Cassano, M. Perticone, G. Sesti, et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension Eur. Heart J., May 1, 2005; 26(9): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mancia and G. Grassi Joint National Committee VII and European Society of Hypertension/European Society of Cardiology Guidelines for Evaluating and Treating Hypertension: A Two-Way Road? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S74 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, F. Angeli, R. Gattobigio, M. Sardone, and C. Porcellati Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension: Prevalence, Determinants, and Prognostic Value Hypertension, March 1, 2005; 45(3): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nunez, D. K. Arnett, E. J. Benjamin, P. R. Liebson, T. N. Skelton, H. Taylor, and M. Andrew Optimal Threshold Value for Left Ventricular Hypertrophy in Blacks: The Atherosclerosis Risk in Communities Study Hypertension, January 1, 2005; 45(1): 58 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kedar, H. McDonough, R. Arya, H.-H. Li, H. A. Rockman, and C. Patterson Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I PNAS, December 28, 2004; 101(52): 18135 - 18140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Okin, R. B. Devereux, S. Jern, S. E. Kjeldsen, S. Julius, M. S. Nieminen, S. Snapinn, K. E. Harris, P. Aurup, J. M. Edelman, et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events JAMA, November 17, 2004; 292(19): 2343 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Devereux, K. Wachtell, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. Harris, P. Aurup, and B. Dahlof Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension JAMA, November 17, 2004; 292(19): 2350 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Fagard, J. A. Staessen, L. Thijs, H. Celis, W. H. Birkenhager, C. J. Bulpitt, P. W. de Leeuw, G. Leonetti, C. Sarti, J. Tuomilehto, et al. Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension Hypertension, October 1, 2004; 44(4): 459 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Devereux, B. Dahlof, E. Gerdts, K. Boman, M. S. Nieminen, V. Papademetriou, J. Rokkedal, K. E. Harris, J. M. Edelman, and K. Wachtell Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial Circulation, September 14, 2004; 110(11): 1456 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, S. Norgiolini, C. Bracco, and C. Porcellati Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects Hypertension, May 1, 2004; 43(5): 963 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Okin, M. J. Roman, E. T. Lee, J. M. Galloway, B. V. Howard, and R. B. Devereux Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians: The Strong Heart Study Hypertension, April 1, 2004; 43(4): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ichinose, K. D. Bloch, J. C. Wu, R. Hataishi, H. T. Aretz, M. H. Picard, and M. Scherrer-Crosbie Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1070 - H1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.D. Witham, J.I. Davies, A. Dawson, P.G. Davey, and A.D. Struthers Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations QJM, February 1, 2004; 97(2): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kyuma, T. Nakata, A. Hashimoto, K. Nagao, H. Sasao, T. Takahashi, K. Tsuchihashi, and K. Shimamoto Incremental Prognostic Implications of Brain Natriuretic Peptide, Cardiac Sympathetic Nerve Innervation, and Noncardiac Disorders in Patients with Heart Failure J. Nucl. Med., February 1, 2004; 45(2): 155 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pontremoli, G. Leoncini, F. Viazzi, D. Parodi, E. Ratto, S. Vettoretti, M. Ravera, C. Tomolillo, and G. Deferrari Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S34 - 36. [Abstract] [Full Text]
|
|
|
|
|
|
T. F. Griffith, D. N. Reddan, P. S. Klassen, and W. F. Owen Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2479 - 2482. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Di Tullio, D. R. Zwas, R. L. Sacco, R. R. Sciacca, and S. Homma Left Ventricular Mass and Geometry and the Risk of Ischemic Stroke Stroke, October 1, 2003; 34(10): 2380 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Devereux, B. Dahlof, S. E. Kjeldsen, S. Julius, P. Aurup, G. Beevers, J. M. Edelman, U. de Faire, F. Fyhrquist, Sigrid Helle Berg, et al. Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial Ann Intern Med, August 5, 2003; 139(3): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. V. Cloward, J. M. Walker, R. J. Farney, and J. L. Anderson Left Ventricular Hypertrophy Is a Common Echocardiographic Abnormality in Severe Obstructive Sleep Apnea and Reverses With Nasal Continuous Positive Airway Pressure Chest, August 1, 2003; 124(2): 594 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Selvetella, A. Notte, A. Maffei, V. Calistri, V. Scamardella, G. Frati, B. Trimarco, C. Colonnese, and G. Lembo Left Ventricular Hypertrophy Is Associated With Asymptomatic Cerebral Damage in Hypertensive Patients Stroke, July 1, 2003; 34(7): 1766 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.D. Struthers and J. Davies Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease? QJM, June 1, 2003; 96(6): 449 - 452. [Full Text] [PDF]
|
|
|
|
|
|
G. de Simone, R. B. Devereux, S. G. Myerson, and D. J. Pennell What Is Bright Is Not Always Gold * Response: What Is Old Is Not Always Best Hypertension, June 1, 2003; e10(6): . [Full Text] [PDF]
|
|
|
|
|
|
K Y K Wong, R S M. Walter, D Douglas, H W Fraser, S A Ogston, and A D Struthers Long QTc predicts future cardiac death in stroke survivors Heart, April 1, 2003; 89(4): 377 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Morisco, J. Sadoshima, B. Trimarco, R. Arora, D. E. Vatner, and S. F. Vatner Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus Am J Physiol Heart Circ Physiol, April 1, 2003; 284 (4): H1043 - H1047. [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakata, K. Yamamoto, T. Mano, N. Nishikawa, J. Yoshida, T. Miwa, M. Hori, and T. Masuyama Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction Cardiovasc Res, March 1, 2003; 57(3): 757 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Angeli, P. Verdecchia, C. Pellegrino, R. G. Pellegrino, G. Pellegrino, L. Prosciutti, C. Giannoni, S. Cianetti, and M. Bentivoglio Association Between Periodontal Disease and Left Ventricle Mass in Essential Hypertension Hypertension, March 1, 2003; 41(3): 488 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Reboldi, R. Gattobigio, M. Bentivoglio, C. Borgioni, F. Angeli, E. Carluccio, M. G. Sardone, and C. Porcellati Atrial Fibrillation in Hypertension: Predictors and Outcome Hypertension, February 1, 2003; 41(2): 218 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text]
|
|
|
|
|
|
S. G. Myerson, H. E. Montgomery, M. J. World, and D. J. Pennell Left Ventricular Mass: Reliability of M-Mode and 2-Dimensional Echocardiographic Formulas Hypertension, November 1, 2002; 40(5): 673 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Indolfi, E. Di Lorenzo, C. Perrino, A. M. Stingone, A. Curcio, D. Torella, A. Cittadini, L. Cardone, C. Coppola, L. Cavuto, et al. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21ras Activation Circulation, October 15, 2002; 106(16): 2118 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D'Aloia, C. Fiorina, E. Vizzardi, P. Faggiano, and L. D. Cas Hypertensive crisis and acute, reversible, left ventricular systolic dysfunction: a case report Eur J Heart Fail, October 1, 2002; 4(5): 655 - 660. [Full Text] [PDF]
|
|
|
|
|
|
A. Sharp and J. Mayet Regression of left ventricular hypertrophy: hoping for a longer life Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 141 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Gardin, D. Brunner, P. J. Schreiner, X. Xie, C. L. Reid, K. Ruth, D. E. Bild, and S. S. Gidding Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) Study J. Am. Coll. Cardiol., August 7, 2002; 40(3): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schrier, K. McFann, A. Johnson, A. Chapman, C. Edelstein, G. Brosnahan, T. Ecder, and L. Tison Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycystic Kidney Disease: Results of a Seven-Year Prospective Randomized Study J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1733 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schillaci, L. Pasqualini, P. Verdecchia, G. Vaudo, S. Marchesi, C. Porcellati, G. de Simone, and E. Mannarino Prognostic significance of left ventricular diastolic dysfunction in essential hypertension J. Am. Coll. Cardiol., June 19, 2002; 39(12): 2005 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Schillaci, C. Borgioni, R. Gattobigio, G. Ambrosio, and C. Porcellati Prevalent influence of systolic over pulse pressure on left ventricular mass in essential hypertension Eur. Heart J., April 2, 2002; 23(8): 658 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. G. De Lima, M. L. C. Vieira, L. F. Viviani, C. J. Medeiros, L. E. Ianhez, L. Kopel, J. L. de Andrade, E. M. Krieger, and S. G. Lage Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients Nephrol. Dial. Transplant., April 1, 2002; 17(4): 645 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Myerson, N. G. Bellenger, and D. J. Pennell Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance Hypertension, March 1, 2002; 39(3): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Struthers Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only Heart, February 1, 2002; 87(2): 97 - 98. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Spratt, D. J Webb, A. Shiels, and B. Williams Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 227 - 232. [Abstract] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Carini, A. Circo, E. Dovellini, E. Giovannini, M. Lombardo, P. Solinas, M. Gorini, A. P. Maggioni, and the MAVI Study Group Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1829 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. London, B. Pannier, A. P. Guerin, J. Blacher, S. J. Marchais, B. Darne, F. Metivier, H. Adda, and M. E. Safar Alterations of Left Ventricular Hypertrophy in and Survival of Patients Receiving Hemodialysis: Follow-up of an Interventional Study J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2759 - 2767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Palmieri, A. Celentano, M. J. Roman, G. de Simone, M. R. Lewis, L. Best, E. T. Lee, D. C. Robbins, B. V. Howard, and R. B. Devereux Fibrinogen and Preclinical Echocardiographic Target Organ Damage: The Strong Heart Study Hypertension, November 1, 2001; 38(5): 1068 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, C. Porcellati, G. Reboldi, R. Gattobigio, C. Borgioni, T. A. Pearson, and G. Ambrosio Left Ventricular Hypertrophy as an Independent Predictor of Acute Cerebrovascular Events in Essential Hypertension Circulation, October 23, 2001; 104(17): 2039 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. E. Heidland and B. E. Strauer Left Ventricular Muscle Mass and Elevated Heart Rate Are Associated With Coronary Plaque Disruption Circulation, September 25, 2001; 104(13): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Devereux, V. Palmieri, N. Sharpe, V. De Quattro, J. N. Bella, G. de Simone, J. F. Walker, R. T. Hahn, and B. Dahlof Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial Circulation, September 11, 2001; 104(11): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perticone, R. Ceravolo, A. Pujia, G. Ventura, S. Iacopino, A. Scozzafava, A. Ferraro, M. Chello, P. Mastroroberto, P. Verdecchia, et al. Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients Circulation, July 10, 2001; 104(2): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schillaci, G. Reboldi, and P. Verdecchia High-Normal Serum Creatinine Concentration Is a Predictor of Cardiovascular Risk in Essential Hypertension Arch Intern Med, March 26, 2001; 161(6): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perlini, M. L. Muiesan, C. Cuspidi, L. Sampieri, B. Trimarco, G. P. Aurigemma, E. Agabiti-Rosei, and G. Mancia Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry Circulation, February 6, 2001; 103(5): 678 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Palmieri, J. N. Bella, D. K. Arnett, J. E. Liu, A. Oberman, M.-Y. Schuck, D. W. Kitzman, P. N. Hopkins, D. Morgan, D. C. Rao, et al. Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects : Hypertension Genetic Epidemiology Network (HyperGEN) Study Circulation, January 2, 2001; 103(1): 102 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J. Am. Coll. Cardiol., January 1, 2001; 37(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Schillaci, G. Reboldi, F. Santeusanio, C. Porcellati, and P. Brunetti Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension : The PIUMA Study Hypertension, December 1, 2000; 36(6): 1072 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.O. Lim and T.M. MacDonald Step test in hypertension QJM, November 1, 2000; 93(11): 703 - 705. [Full Text] [PDF]
|
|
|
|
|
|
J. Mayet, B. Ariff, B. Wasan, N. Chapman, M. Shahi, N. R. Poulter, P. S. Sever, R. A. Foale, and S. A. McG. Thom Improvement in Midwall Myocardial Shortening With Regression of Left Ventricular Hypertrophy Hypertension, November 1, 2000; 36(5): 755 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rajappan, N. G. Bellenger, L. Anderson, and D. J. Pennell The role of cardiovascular magnetic resonance in heart failure Eur J Heart Fail, September 1, 2000; 2(3): 241 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tamura, S. Said, J. Harris, W. Lu, and A. M. Gerdes Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System Circulation, July 11, 2000; 102(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Gottdiener, A. M. Arnold, G. P. Aurigemma, J. F. Polak, R. P. Tracy, D. W. Kitzman, J. M. Gardin, J. E. Rutledge, and R. C. Boineau Predictors of congestive heart failure in the elderly: the cardiovascular health study J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1628 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. FOLEY, P. S. PARFREY, G. M. KENT, J. D. HARNETT, D. C. MURRAY, and P. E. BARRE Serial Change in Echocardiographic Parameters and Cardiac Failure in End-Stage Renal Disease J. Am. Soc. Nephrol., May 1, 2000; 11(5): 912 - 916. [Abstract] [Full Text]
|
|
|
|
|
|
P. Verdecchia Prognostic Value of Ambulatory Blood Pressure : Current Evidence and Clinical Implications Hypertension, March 1, 2000; 35(3): 844 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schillaci, P. Verdecchia, C. Porcellati, O. Cuccurullo, C. Cosco, and F. Perticone Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension Hypertension, February 1, 2000; 35(2): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parati, L. Ulian, L. Sampieri, P. Palatini, A. Villani, A. Vanasia, and G. Mancia Attenuation of the "White-Coat Effect" by Antihypertensive Treatment and Regression of Target Organ Damage Hypertension, February 1, 2000; 35(2): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Palmieri, B. Dahlof, V. DeQuattro, N. Sharpe, J. N. Bella, G. de Simone, M. Paranicas, D. Fishman, and R. B. Devereux Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Modena, N. Muia Jr, P. Aveta, R. Molinari, and R. Rossi Effects of Transdermal 17{beta}-Estradiol on Left Ventricular Anatomy and Performance in Hypertensive Women Hypertension, November 1, 1999; 34(5): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Reboldi, G. Schillaci, C. Borgioni, A. Ciucci, M. P. Telera, F. Santeusanio, C. Porcellati, and P. Brunetti Circulating Insulin and Insulin Growth Factor-1 Are Independent Determinants of Left Ventricular Mass and Geometry in Essential Hypertension Circulation, October 26, 1999; 100(17): 1802 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mosterd, R. B. D'Agostino, H. Silbershatz, P. A. Sytkowski, W. B. Kannel, D. E. Grobbee, and D. Levy Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989 N. Engl. J. Med., April 22, 1999; 340(16): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perticone, R. Maio, R. Ceravolo, C. Cosco, C. Cloro, and P. L. Mattioli Relationship Between Left Ventricular Mass and Endothelium-Dependent Vasodilation in Never-Treated Hypertensive Patients Circulation, April 20, 1999; 99(15): 1991 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schirmer, P. Lunde, and K. Rasmussen Prevalence of left ventricular hypertrophy in a general population; The Tromso Study Eur. Heart J., March 2, 1999; 20(6): 429 - 438. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Phillips, L. R. Krakoff, A. Dunaif, D. T. Finegood, R. Gorlin, and S. Shimabukuro Relation among Left Ventricular Mass, Insulin Resistance, and Blood Pressure in Nonobese Subjects J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4284 - 4288. [Abstract] [Full Text]
|
|
|
|
|
|
P. Verdecchia, G. Schillaci, C. Borgioni, A. Ciucci, S. Pede, and C. Porcellati Ambulatory Pulse Pressure : A Potent Predictor of Total Cardiovascular Risk in Hypertension Hypertension, December 1, 1998; 32(6): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Haider, M. G. Larson, E. J. Benjamin, and D. Levy Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1454 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Left Ventricular Hypertrophy and Hypertension Journal Watch Cardiology, February 17, 1998; 1998(217): 10 - 10. [Full Text]
|
|